David Craig's book, The New Rules of Biotech: A Founder's Guide to Building Great Companies, is now available in hardcover ($29.99) and as an audiobook on Google Play, joining the paperback ($21.99) and Kindle ($11.99) editions already on Amazon. The book addresses the changed landscape for biotechnology startups, where capital is expensive, FDA standards have shifted, and the Inflation Reduction Act has altered drug economics.
Craig draws on his experience founding Sarcomatrix Therapeutics to provide a practical operating manual. Topics include choosing between a platform and an asset, selecting an affordable modality, raising seed rounds against milestones, and using non-dilutive capital strategically. The book covers IND-enabling work, CMC, clinical decisions, term sheets, boards, business development, and exits like acquisitions and IPOs.
The book is written for founders, investors, board members, and operators, with each chapter closing with separate takeaways for operators and investors. The audiobook format allows listeners to absorb the material on the go.
The book's origin stems from Craig's family connection to a rare genetic muscle disease, RYR-1 related congenital muscular dystrophy, which informs his argument that biotech company building carries a responsibility beyond returns.
“Founders and operators take in ideas in different ways,” said David Craig. “The hardcover is there for the people who want a durable copy on the desk, the paperback and Kindle for everyone else, and the audiobook on Google Play for those who prefer to listen on the move. The message is the same across all of them: build for the market that exists now, not the one that existed in 2021.”
The book is published by D. Craig Consulting LLC and is available at Amazon in hardcover (https://www.amazon.com/dp/B0H5KN1BLW), paperback (https://www.amazon.com/dp/B0H4WZV6CW), and Kindle (https://www.amazon.com/dp/B0GX38YLJ7), and as an audiobook on Google Play (https://play.google.com/store/audiobooks/details?id=AQAAAEB6fmE-CM).
